ArticleThe pharmacogenomics journal2016

AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.

J B Kjersem et al.PubMed ↗Publisher ↗

No numbers read from the abstract.